Residual cancer burden index - Revision history

Michael at 00:11, 16 October 2024

2024-10-16T00:11:16Z

← Older revision		Revision as of 00:11, 16 October 2024
Line 25:		Line 25:
	==See also==		==See also==
	*[[Neoadjuvant therapy]].		*[[Neoadjuvant therapy]].
			*[[Lung cancer after neoadjuvant therapy]].

	==References==		==References==

Michael at 23:58, 15 October 2024

2024-10-15T23:58:17Z

← Older revision		Revision as of 23:58, 15 October 2024
Line 21:		Line 21:
	*High risk (RCB-III): RCB > 3.28.		*High risk (RCB-III): RCB > 3.28.

	If one includes the group without any residual disease: there are four groups (RCB-0, RCB-I, RCB-II, RCB-III).		If one includes the group without any residual disease, there are four groups: RCB-0, RCB-I, RCB-II, RCB-III.

	==See also==		==See also==

Michael at 23:57, 15 October 2024

2024-10-15T23:57:54Z

← Older revision		Revision as of 23:57, 15 October 2024
Line 20:		Line 20:
	*Intermediate risk (RCB-II): RCB > 1.36 and < 3.28.		*Intermediate risk (RCB-II): RCB > 1.36 and < 3.28.
	*High risk (RCB-III): RCB > 3.28.		*High risk (RCB-III): RCB > 3.28.

			If one includes the group without any residual disease: there are four groups (RCB-0, RCB-I, RCB-II, RCB-III).

	==See also==		==See also==

Michael at 23:56, 15 October 2024

2024-10-15T23:56:48Z

← Older revision		Revision as of 23:56, 15 October 2024
Line 14:		Line 14:
	:<math>d_1 = \text{first in-plane tumour dimension}</math>		:<math>d_1 = \text{first in-plane tumour dimension}</math>
	:<math>d_1 = \text{second in-plane tumour dimension}</math>		:<math>d_1 = \text{second in-plane tumour dimension}</math>

			==Interpretation==
			The original paper stratified patients into three groups using two cut-points:<ref name=pmid17785706/>
			*Low risk (RCB-I): RCB > 0 and < 1.36.
			*Intermediate risk (RCB-II): RCB > 1.36 and < 3.28.
			*High risk (RCB-III): RCB > 3.28.

	==See also==		==See also==

Michael at 23:49, 15 October 2024

2024-10-15T23:49:52Z

← Older revision		Revision as of 23:49, 15 October 2024
Line 4:		Line 4:
	The [[RCB index]] is defined as:<ref name=pmid17785706>{{cite journal \|authors=Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L \|title=Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy \|journal=J Clin Oncol \|volume=25 \|issue=28 \|pages=4414–22 \|date=October 2007 \|pmid=17785706 \|doi=10.1200/JCO.2007.10.6823 \|url=}}</ref>		The [[RCB index]] is defined as:<ref name=pmid17785706>{{cite journal \|authors=Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L \|title=Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy \|journal=J Clin Oncol \|volume=25 \|issue=28 \|pages=4414–22 \|date=October 2007 \|pmid=17785706 \|doi=10.1200/JCO.2007.10.6823 \|url=}}</ref>
	:<math>RCB = 1.4 \ ( f_{inv} \ d_{prim} )^ {0.17} + \lbrack{ \ 4 \ (1 - 0.75^{LN}) d_{met}} \rbrack ^{0.17}</math>		:<math>RCB = 1.4 \ ( f_{inv} \ d_{prim} )^ {0.17} + \lbrack{ \ 4 \ (1 - 0.75^{LN}) d_{met}} \rbrack ^{0.17}</math>

			Where:
			:<math>f_{inv} = \text {portion of tumour bed that is viable invasive tumour}</math>
			:<math>d_{prim} = \sqrt {d_1 \ d_2}</math>
			:<math>\text{LN} = \text {number of lymph nodes with metastatic carcinoma}</math>
			:<math>d_{met} = \text {diameter of the largest lymph node metastasis}</math>

			The inputs to <math>d_{prim}</math> are:
			:<math>d_1 = \text{first in-plane tumour dimension}</math>
			:<math>d_1 = \text{second in-plane tumour dimension}</math>

	==See also==		==See also==

Michael at 23:40, 15 October 2024

2024-10-15T23:40:27Z

← Older revision		Revision as of 23:40, 15 October 2024
Line 2:		Line 2:

	==Definition==		==Definition==
	The [[RCB index]] is defined as:		The [[RCB index]] is defined as:<ref name=pmid17785706>{{cite journal \|authors=Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L \|title=Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy \|journal=J Clin Oncol \|volume=25 \|issue=28 \|pages=4414–22 \|date=October 2007 \|pmid=17785706 \|doi=10.1200/JCO.2007.10.6823 \|url=}}</ref>
	:<math>RCB = 1.4 \ ( f_{inv} \ d_{prim} )^ {0.17} + \lbrack{ \ 4 \ (1 - 0.75^{LN}) d_{met}} \rbrack ^{0.17}</math>		:<math>RCB = 1.4 \ ( f_{inv} \ d_{prim} )^ {0.17} + \lbrack{ \ 4 \ (1 - 0.75^{LN}) d_{met}} \rbrack ^{0.17}</math>

Michael at 23:39, 15 October 2024

2024-10-15T23:39:07Z

← Older revision		Revision as of 23:39, 15 October 2024
Line 1:		Line 1:
	'''Residual cancer burden index''', abbreviated '''RCB''', is an empirical predictor of outcome in [[breast cancer]] in the [[post-neoadjuvant therapy]] setting.<ref>{{cite journal \|authors=Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S, Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JM, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF \|title=Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients \|journal=Lancet Oncol \|volume=23 \|issue=1 \|pages=149–160 \|date=January 2022 \|pmid=34902335 \|doi=10.1016/S1470-2045(21)00589-1 \|url=}}</ref>		'''Residual cancer burden index''', abbreviated '''RCB''', is an empirical predictor of outcome in [[breast cancer]] in the [[post-neoadjuvant therapy]] setting.<ref>{{cite journal \|authors=Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S, Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JM, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF \|title=Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients \|journal=Lancet Oncol \|volume=23 \|issue=1 \|pages=149–160 \|date=January 2022 \|pmid=34902335 \|doi=10.1016/S1470-2045(21)00589-1 \|url=}}</ref>

			==Definition==
			The [[RCB index]] is defined as:
			:<math>RCB = 1.4 \ ( f_{inv} \ d_{prim} )^ {0.17} + \lbrack{ \ 4 \ (1 - 0.75^{LN}) d_{met}} \rbrack ^{0.17}</math>

	==See also==		==See also==
Line 6:		Line 10:
	==References==		==References==
	{{Reflist\|1}}		{{Reflist\|1}}

			==External links==
			*[https://www3.mdanderson.org/app/medcalc/index.cfm?pagename=jsconvert3 Online calculator for RCB index (mdanderson.org)].

	[[Category:Breast pathology]]		[[Category:Breast pathology]]

Michael at 23:26, 15 October 2024

2024-10-15T23:26:39Z

← Older revision		Revision as of 23:26, 15 October 2024
Line 1:		Line 1:
	'''Residual cancer burden index''', abbreviated '''RCB''', is an empirical predictor of outcome in [[breast cancer]] in the [[post-neoadjuvant therapy]] setting.<ref>{{cite journal \|authors=Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S, Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JM, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF \|title=Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients \|journal=Lancet Oncol \|volume=23 \|issue=1 \|pages=149–160 \|date=January 2022 \|pmid=34902335 \|doi=10.1016/S1470-2045(21)00589-1 \|url=}}</ref>		'''Residual cancer burden index''', abbreviated '''RCB''', is an empirical predictor of outcome in [[breast cancer]] in the [[post-neoadjuvant therapy]] setting.<ref>{{cite journal \|authors=Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S, Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JM, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF \|title=Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients \|journal=Lancet Oncol \|volume=23 \|issue=1 \|pages=149–160 \|date=January 2022 \|pmid=34902335 \|doi=10.1016/S1470-2045(21)00589-1 \|url=}}</ref>

			==See also==
			*[[Neoadjuvant therapy]].

	==References==		==References==

Michael: Created page with "'''Residual cancer burden index''', abbreviated '''RCB''', is an empirical predictor of outcome in breast cancer in the post-neoadjuvant therapy setting.{{cite jo..."

2024-10-15T23:26:14Z

Created page with "'''Residual cancer burden index''', abbreviated '''RCB''', is an empirical predictor of outcome in breast cancer in the post-neoadjuvant therapy setting.<ref>{{cite jo..."

New page

'''Residual cancer burden index''', abbreviated '''RCB''', is an empirical predictor of outcome in [[breast cancer]] in the [[post-neoadjuvant therapy]] setting.<ref>{{cite journal |authors=Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S, Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JM, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF |title=Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients |journal=Lancet Oncol |volume=23 |issue=1 |pages=149–160 |date=January 2022 |pmid=34902335 |doi=10.1016/S1470-2045(21)00589-1 |url=}}</ref>

==References==
{{Reflist|1}}

[[Category:Breast pathology]]